WO2013173803A3 - Formulations of amoxicillin and clavulanate potassium and methods for using same - Google Patents

Formulations of amoxicillin and clavulanate potassium and methods for using same Download PDF

Info

Publication number
WO2013173803A3
WO2013173803A3 PCT/US2013/041719 US2013041719W WO2013173803A3 WO 2013173803 A3 WO2013173803 A3 WO 2013173803A3 US 2013041719 W US2013041719 W US 2013041719W WO 2013173803 A3 WO2013173803 A3 WO 2013173803A3
Authority
WO
WIPO (PCT)
Prior art keywords
amoxicillin
clavulanate potassium
formulations
methods
same
Prior art date
Application number
PCT/US2013/041719
Other languages
French (fr)
Other versions
WO2013173803A2 (en
Inventor
Michael Spector
Original Assignee
Michael Spector
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Michael Spector filed Critical Michael Spector
Publication of WO2013173803A2 publication Critical patent/WO2013173803A2/en
Publication of WO2013173803A3 publication Critical patent/WO2013173803A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The invention is directed to a composition containing amoxicillin and clavulanate potassium where the clavulanate potassium is present in an amount equal to or less than about 21,5 mg/5 mL.
PCT/US2013/041719 2012-05-17 2013-05-17 Formulations of amoxicillin and clavulanate potassium and methods for using same WO2013173803A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261648579P 2012-05-17 2012-05-17
US61/648,579 2012-05-17

Publications (2)

Publication Number Publication Date
WO2013173803A2 WO2013173803A2 (en) 2013-11-21
WO2013173803A3 true WO2013173803A3 (en) 2015-06-25

Family

ID=49584479

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2013/041719 WO2013173803A2 (en) 2012-05-17 2013-05-17 Formulations of amoxicillin and clavulanate potassium and methods for using same

Country Status (1)

Country Link
WO (1) WO2013173803A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018005830A1 (en) * 2016-06-29 2018-01-04 Otonomy, Inc. Triglyceride otic formulations and uses thereof
CN114869884A (en) * 2021-07-30 2022-08-09 江苏恒丰强生物技术有限公司 Compound amoxicillin powder for porcine respiratory diseases and preparation method thereof

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1013274A2 (en) * 1995-05-03 2000-06-28 Smithkline Beecham Plc Composition comprising amoxycillin and clavulanic acid
US6214359B1 (en) * 1996-08-24 2001-04-10 Smithkline Beecham P.L.C. Use of a combination of amoxycillin and clavulanate in the manufacture of a medicament for the treatment drug-resistant Streptococcus pneumoniae
US6511972B1 (en) * 1998-07-17 2003-01-28 Lek Pharmaceutical & Chemical Company D.D. Pharmaceutical suspension formulation comprising amoxycillin clavulanic acid and cellulose
US6726908B2 (en) * 1995-09-07 2004-04-27 Smithkline Beecham P.L.C. Pharmaceutical formulation
US7011849B2 (en) * 2000-10-12 2006-03-14 Beecham Pharmaceuticals (Pte) Limited Second release phase formulation
US20060115528A1 (en) * 2002-06-21 2006-06-01 Vesna Skulj Rapidly disintegrating tablet
WO2013106601A1 (en) * 2012-01-10 2013-07-18 Michael Spector Pediatric oral suspension formulations of amoxicillin and clavulanate potassium and method for using same

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1013274A2 (en) * 1995-05-03 2000-06-28 Smithkline Beecham Plc Composition comprising amoxycillin and clavulanic acid
US6726908B2 (en) * 1995-09-07 2004-04-27 Smithkline Beecham P.L.C. Pharmaceutical formulation
US6214359B1 (en) * 1996-08-24 2001-04-10 Smithkline Beecham P.L.C. Use of a combination of amoxycillin and clavulanate in the manufacture of a medicament for the treatment drug-resistant Streptococcus pneumoniae
US6511972B1 (en) * 1998-07-17 2003-01-28 Lek Pharmaceutical & Chemical Company D.D. Pharmaceutical suspension formulation comprising amoxycillin clavulanic acid and cellulose
US7011849B2 (en) * 2000-10-12 2006-03-14 Beecham Pharmaceuticals (Pte) Limited Second release phase formulation
US20060115528A1 (en) * 2002-06-21 2006-06-01 Vesna Skulj Rapidly disintegrating tablet
WO2013106601A1 (en) * 2012-01-10 2013-07-18 Michael Spector Pediatric oral suspension formulations of amoxicillin and clavulanate potassium and method for using same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KERC ET AL.: "A new amoxicittin/clavulanate therapeutic system: Preparation, in vitro and pharmacokinetic evaluation", INTERNATIONAL JOURNAL OF PHARMACEUTICS, vol. 335, 2007, pages 106 - 113 *

Also Published As

Publication number Publication date
WO2013173803A2 (en) 2013-11-21

Similar Documents

Publication Publication Date Title
AU2012265219A8 (en) Compounds containing hydrido-tricyano-borate anions
WO2014039903A3 (en) Stable aqueous formulations of adalimumab
WO2012021715A3 (en) Stable formulations of linaclotide
UA104005C2 (en) 2-oxo-1,2-dihydro-quinoline modulators of immune function
MX338515B (en) Tetrahydroquinoline derivatives useful as bromodomain inhibitors.
WO2014066468A8 (en) Stable, low viscosity antibody formulation
MX2019009176A (en) Etanercept formulations stabilized with metal ions.
WO2012118812A3 (en) Substituted 6,5-fused bicyclic heteroaryl compounds
WO2011017502A3 (en) Linaclotide-containing formulations for oral administration
WO2014023640A3 (en) Cosmetic compositions
MX2015000813A (en) Liposomal compositions of epoxyketone-based proteasome inhibitors.
BR112015000229A2 (en) stable aqueous formulations of etanercept
WO2014086982A3 (en) Stable metal compounds, their compositions and methods of their use
WO2013057013A3 (en) Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
WO2011140341A3 (en) Cosmetic compositions containing acrylic thickener
EP3878445A3 (en) Acamprosate formulations, methods of using the same, and combinations comprising the same
WO2014121040A8 (en) Flap modulators
WO2014121055A3 (en) Flap modulators
MX2015000179A (en) Itraconazole compositions and dosage forms, and methods of using the same.
MX356373B (en) Compositions comprising antibacterial agent and tazobactam.
WO2011139252A3 (en) Efervescent formulations comprising cefdinir
WO2013173803A3 (en) Formulations of amoxicillin and clavulanate potassium and methods for using same
WO2014166836A8 (en) Growth hormone compound formulation
AU2012345659A8 (en) Acamprosate formulations, methods of using the same, and combinations comprising the same
UA110131C2 (en) Normal;heading 1;heading 2;heading 3;THIENO [2,3 -D] PYRIMIDINE DERIVATIVES AND THEIR USE TO TREAT ARRHYTHMIA

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13790084

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 13790084

Country of ref document: EP

Kind code of ref document: A2